arrow
D

Diego Cortinovis

University of Milano-Bicocca
H指数:46
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2026-09-080
OAAI
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study

根据KRAS状态评估一线化疗联合免疫疗法在晚期非鳞状NSCLC中的疗效:一项意大利真实世界研究

2026-08-010
PRE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

纳武利尤单抗联合放化疗后序贯纳武利尤单抗联合或不联合伊匹木单抗治疗未经治疗的局部晚期Ⅲ期非小细胞肺癌:一项随机Ⅲ期试验

2026-05-130
OAAI
Retrospective evaluation of the neutrophil-lymphocyte ratio (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial

意大利扩大准入计划(EAP)中接受度鲁鲁单抗治疗的局部晚期不可切除III期非小细胞肺癌(NSCLC)患者中性粒细胞与淋巴细胞比值(NLR)的回顾性评估:中性试验的结果

2026-02-010
OAAI
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Lung Multidisciplinary Team Decision-Making Challenges in Perioperative NSCLC: Borderline Resectability and Discordant Responses Through the Lens of Real-World Scenarios

肺癌多学科团队围手术期决策挑战:通过真实世界场景观察的可切除性边缘病例与意见不一致的应对

Cancers
IF4.4
2026-01-010
OA
A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients

关于PD-(L)1抑制剂在亚洲和非亚洲患者中用于局部晚期或转移性非小细胞肺癌的一线及二线治疗的有效性和安全性的系统文献综述和荟萃分析

2025-12-310
PRE
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial

曲妥珠单抗德鲁替康在HER2过表达的非小细胞肺癌患者中的疗效:开放标签、多中心、Ⅰb期DESTINY-Lung03试验第一部分的结果

2025-12-230
OAAI
Correction: Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

更正:卡马替尼用于治疗METex14跳读的非小细胞肺癌:意大利接受同情用药治疗患者的真实世界数据回顾性分析

2025-12-180
OAAI
Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

卡马替尼治疗METex14跳读非小细胞肺癌:意大利接受同情用药治疗患者真实世界数据的回顾性分析

2025-11-180
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

EGFR突变晚期非小细胞肺癌患者在接受一线奥希替尼治疗后,接受卡铂联合培美曲塞二线治疗的实际疗效:一项国际多中心队列研究

2025-10-160
PRE
Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT

下一代放射组学测序在非小细胞肺癌中的应用:一种用于从[18F]FDG PET/CT预测突变的替代模型

2025-10-090
OA
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer

作者更正:对3600多种肿瘤中KEAP1/NFE2L2变异的整合分析揭示了NRF2表达谱是一种癌症预后生物标志物

2025-09-160
OAAI